Auk sales

Full year sales rise 50% to $39mAumake Limited (ASX: AUK) (Aumake or the Company) updates shareholders that fullyear revenues are expected to rise by over 50% vs FY24 to over $39m AUD (preliminary,unaudited results) compared to $25.87m in FY24.Chairman, Dr Anthony Noble, commented on the expected result “As China Australiatrade relations materially thaw, few companies stand better positioned to capitalise onthe increased focus on trade between the two countries than Aumake Limited. Thecompany’s sales results in the full year ended 30 June 2025 are expected to eclipse $39mAUD, up from $26m in FY24 – cementing our status as one of the only ASX listed companiesthat can execute on meaningful, long-term sales into the China market.“In FY26, the company is evolving and maturing our strategy to more profitably exploit ourenviable distribution capabilities in the Chinese market though several key strategicobjectives. These include transitioning our substantial cross border and China retail B2Band B2C business units to lower cost models, exploring new sales channels via Pilot Zonedistribution into China Hospital Pharmacies, and activating sales of our own brandedproducts, such as BioBasics, in China and the USA through our NewEra / ZoomCoopartnership. These new objectives build on our strong brand partnerships with Danone,Kabrita and other foundational cross-border brand leaders.“To more effectively deliver on this strategy and further reduce our fixed cost base thecompany has recently announced a corporate restructuring into two business units thatwill significantly simplify our executive team, board and subsidiary structures. Therestructure will give shareholders and investors more clarity on the various businessactivities, profitability and sales growth in the company. At the highest level, therestructure positions Aumake as a brand incubation business that can be agile in newmarket entry and capitalise on success via acquisition of successful brands in ourecosystem, as they reach maturity, all while prudently deploying shareholder capital.”This release has been approved by the board of directorsends